Related Experiment Video
Updated: May 1, 2026
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Four cases of rituximab-associated melanoma
Charles Velter1, Cécile Pagès, Pierre Schneider
1Departments of aDermatology bHemato-oncology cAnatomo-pathology, Saint Louis Hospital, Paris Cedex 10, France.
Abstract:
Biological agents have transformed the management of inflammatory and proliferative disorders. Safety issues have been raised, particularly the increased risk of opportunistic infections and secondary cancers. We report four cases of melanoma worsening or occurring after rituximab treatment for associated B-cell lymphoma, and discuss the accountability of the molecule in this process. In three cases, melanoma was diagnosed before or at the same time as a B-cell lymphoma treated with rituximab associated with chemotherapy and we observed rapid metastatic progression. In the last case, melanoma appeared after 5 years treatment with rituximab for a follicular lymphoma. Although it is premature to conclude on the role of rituximab in melanoma, careful follow-up and registration of such cases are important to gain further insight on this topic.
Insights
Rituximab treatment for B-cell lymphoma may be linked to melanoma development or worsening. Further research is needed to understand the association between rituximab and melanoma progression.
Area of Science:
- Oncology
- Immunology
Background:
- Biological agents, such as rituximab, are vital in treating inflammatory and proliferative disorders.
- Safety concerns include increased risks of opportunistic infections and secondary cancers.
Observation:
- Four cases of melanoma worsening or occurring after rituximab treatment for B-cell lymphoma are reported.
- In three cases, melanoma was diagnosed concurrently with B-cell lymphoma treated with rituximab and chemotherapy, showing rapid metastatic progression.
- In one case, melanoma appeared after five years of rituximab treatment for follicular lymphoma.
Findings:
- The study investigates the potential role of rituximab in melanoma progression.
- While a definitive causal link is premature, the observed cases warrant further investigation.
- Close monitoring and data collection of such instances are crucial.
Implications:
- This study highlights the need for vigilance regarding potential adverse events, specifically melanoma, in patients treated with rituximab.
- Further research and data collection are essential to elucidate the relationship between rituximab and melanoma.
- Informing clinical practice and patient monitoring strategies for rituximab-treated patients is important.
